Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18905268 | 0.83 | ALOX5AP (0.39) | ALOX5APHSD11B1PTGS2KMT2A | |
| SCHEMBL11893304 | 0.83 | KMT2A (0.47) | ALOX5APHSD11B1KCNH2KMT2A | |
| SCHEMBL87608 | 0.83 | HSD11B1 (0.55) | ALOX5APHSD11B1PTGS2KMT2A | |
| SCHEMBL3582800 | 0.82 | ALOX5AP (0.51) | ALOX5APHSD11B1PTGS2KMT2A | |
| SCHEMBL12948046 | 0.79 | HSD11B1 (0.39) | ALOX5APHSD11B1 | |
| SCHEMBL18905475 | 0.76 | ALOX5AP (0.38) | ALOX5APHSD11B1PTGS2 | |
| SCHEMBL18910945 | 0.76 | ALOX5AP (0.38) | ALOX5APHSD11B1PTGS2KMT2A | |
| SCHEMBL19901092 | 0.76 | ALOX5AP (0.36) | ALOX5APHSD11B1 | |
| SCHEMBL12920588 | 0.76 | ALOX5AP (0.56) | ALOX5APHSD11B1 | |
| SCHEMBL12920590 | 0.76 | ALOX5AP (0.56) | ALOX5APHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2009048547-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | PTGIS, PTGS1, LTC4S | ALOX5AP 47/4885HSD11B1 252/4885CXCR3 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.